A Phase II Study of Ipilimumab in Combination With Carboplatin and Paclitaxel in Patients With Unresectable Stage III or Stage IV Melanoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Ipilimumab (Primary) ; Carboplatin; Paclitaxel
- Indications Malignant melanoma
- Focus Adverse reactions
- 28 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 28 Feb 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
- 24 Jun 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov.